Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm
Authors Dong H, Fan S, Luo Y, Peng B
Received 29 July 2018
Accepted for publication 27 October 2018
Published 19 December 2018 Volume 2019:15 Pages 33—36
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Papan Thaipisuttikul
Peer reviewer comments 2
Editor who approved publication: Dr Yu-Ping Ning
Hongjuan Dong, Shanghua Fan, Ying Luo, Bin Peng
Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Objective: To explore the efficacy of botulinum toxin type A (BTX-A) therapy in relieving anxiety and depression in patients with hemifacial spasm (HFS) and benign essential blepharospasm (BEB).
Patients and method: Ninety idiopathic HFS patients and 90 BEB patients were enrolled. The anxiety and depression status were evaluated by self-rating anxiety scale (SAS) and self-rating depression scale (SDS), respectively, before and after the injection of BTX-A.
Results: Before treatment, the SAS and SDS scores of HFS patients were 41.25±6.35 and 42.25±7.57, respectively. The SAS scores were 40.17±8.36 for males and 43.56±6.10 for females (P=0.031). The SDS scores were 40.25±6.46 for males and 45.48±7.31 for females (P=0.008). After treatment, the SAS and SDS scores were 30.12±4.35 and 30.58±4.89, respectively. There was a significant difference in the SAS and SDS scores before and after treatment. Before treatment, the SAS scores of male and female BEB patients were 56.45±8.75 and 60.89±9.11, respectively, and the SDS scores of male and female BEB patients were 57.90±7.93 and 60.12±8.35, respectively. After treatment, the SAS score was 38.17±3.67 and the SDS score was 38.12±4.15, with a significant difference in before and after treatment scores.
Conclusion: In HFS and BEB, especially in female patients, there is an association with anxiety and depression. BTX-A can improve the symptoms of anxiety and depression.
Keywords: hemifacial spasm, blepharospasm, anxiety, depression, botulinum toxin type A
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]